QualityDipStocks / Health Care · Pharmaceuticals
Xeris Biopharma XERS
Outside our quality screen, so we don’t track its dips. It’s 9% below its 52-week high.
Outside our quality screen, 9% over its Market Value. No fair value estimate for now: there isn’t enough data.
- Fair value est.
- n/a
- Market Value
- $9.31price +9%
- Off 52-wk high
- −9%
- Risk vs market
- Below marketbeta 0.87
52-week range 84% of the way from its 52-week low to its high
Price $10.17Market Value $9.31
4 bullish · 5 bearish See why
Repriced or dip?
Near its high
The price is 9% below its 52-week high (Oct 20), but the business held up: net cash (cash minus debt) 0.0% of market cap since the high, operating margin 0.0 pts.
Some numbers held up (net cash (cash minus debt) 0.0% of market cap since the high, operating margin 0.0 pts), others slipped (shares outstanding more shares, each owns less). The price is 9% below its 52-week high.
The price is 9% below its 52-week high, and the business changed too: shares outstanding more shares, each owns less.
Within 10% of its 52-week high, so there is no dip to judge yet.
Data-based read, not advice.
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
52-wk low: P/E 1649.5×.
| High | Low | Now | |
|---|---|---|---|
| Price | $11.13Oct 20 | $5.29Mar 24 | $10.17 |
| Implied growth | n/a | n/a | n/a |
| P/E | n/a | 1649.5× | n/a |
| EV/Sales | 6.1× | 3.5× | 6.1× |
What this means: a lower P/E than at the high means you pay less for each dollar of profit than buyers did then.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for XERS: Capital spending isn't tagged for the latest period in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much XERS moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves a bit less than the market, and its own price swings are 4.2× the S&P 500’s.
- Beta vs S&P 500
- 0.87
- Volatility
- 54% vs 13% SPY
- Correlation SPY
- 0.21
- Correlation QQQ
- 0.16
How it ranks
Where XERS stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Top quarter on 2 of 4 measures
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 2,227
- Revenue growth, last 12 months+36% · vs the 12 months beforeTop 12%of 2,184
- Operating margin11% · of sales kept as operating profitTop 50%of 1,549
- Return on invested capital24% · profit per dollar of capitalTop 15%of 1,001
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $9.31 · FCF value $6.69
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ProfitabilityOperating margin widened to 8.5% in FY2025 from −26.8% in FY2023 (SEC filings).
GrowthSales compounded 38% a year from FY2022 to FY2025.
GrowthSales grew 36% to $335M over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityReturn on invested capital of 24%, above the 9.5% discount rate our DCF uses.
Top bearish points 5 of 5
Balance sheetOperating income covers interest only 1.3× over the last 12 months.
ProfitabilityLost $17M over the last 12 months (net income, SEC filings).
Cash returnsShare count up 8.4% in a year: existing holders are being diluted.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%; net debt 3.4× EBITDA (limit 3×).
ValuationTrades 9.2% above its Market Value of $9.31, the average price paid since the Aug 6 filing.
All fundamentals
Sales +36%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- 53.5×
- Price / sales
- 5.66×
- Price / book
- n/anot reported in its SEC filings
- Market cap
- $1.9Blisted
- Enterprise value
- $2.0B
Growth
- Revenue, 12 months
- $335M
- Sales growth, 12 months
- +36.3%vs the 12 months before
- Sales growth, 3 yrs
- +38.3%/yrfrom FY2022
- Diluted EPS, 12 months
- −$0.10
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$17M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- 10.9%
- Net margin
- −5.1%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- n/anegative shareholder equity
- Return on invested capital
- 24%
Balance sheet
- Cash & short-term inv.
- $122M
- Total debt
- $253M
- Net cash
- −$131M
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- 1.3×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +8.4%diluted shares vs a year ago
- Stock-based comp
- $28M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Xeris Biopharma’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.1B · Sales +29%
- Free cash flow, 12 months$0.1B
- Free-cash-flow yield2.6%
- Free-cash-flow margin16%
- Gross margin87%
- Operating margin6%
- Return on invested capital10%
- Sales growth (latest quarter vs year-ago quarter)+29%
- Net debt / EBITDA3.4×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $10.17
- 52-wk lowlowest close, 1 year$5.29−48.0%
- Market Valueavg paid since Aug 6$9.31−8.5%
- PriceMon Nov 2 close$10.17you are here
- 52-wk highhighest close, 1 year$11.13+9.4%
Momentum & 52-week range
RSI 51 · 5 days −0.4%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 5
- DateThu Nov 5, before the open
- Consensus EPS$0.02
- Year-ago EPSN/A
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
XERS is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Xeris Biopharma in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.